Mural Oncology plc

Dozens of public biopharmaceutical companies have announced plans in 2025 to assess strategic alternatives after clinical trial setbacks or as cash stockpiles dwindled. Both ESSA Pharma and Elevation

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

“How does it feel that you have a billion-dollar neuroscience commercial business, and no one cares?” That’s the question an investor asked Alkermes’ chief operating officer Blair Jackson at the recen